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ABSTRACT 
 
Diagnostic assays of reproductive hormones are usually performed by veterinarians on 
mares after inconclusive findings from trans-rectal palpation or ultrasound genital examination, 
or on intractable mares. Of the reproductive hormones, progesterone (P4) is one of the most 
commonly measured hormones in the field of equine reproduction. Serum concentration of P4 
from mares is usually evaluated using an extracted radioimmunoassay (RIA). The use of RIA for 
serum P4 measurement usually involves an extraction process to dissociate the steroids in blood 
from carrier proteins, which bind more close to 90 to 95% of the steroid hormone present. 
Estimation of salivary steroid hormones presents an attractive alternative, since the steroids are 
not protein bound and represent the free fraction which appears to represent the biologically 
active form. The objective of this study was to develop and validate a sensitive and specific RIA 
for estimation of salivary P4 concentration and evaluate its usefulness in identifying the stage of 
the estrous cycle and early pregnancy in mares. Serum and saliva samples were collected on 
selected days of the estrous cycle and early pregnancy (up to day 65) from mares and were 
validated using a liquid phase RIA. Saliva samples did not require solvent extraction and were 
run without this processing step. The inter-assay coefficient of variation (CV) for low and high 
controls was 6.91% ± 0.81 (Mean ± S.E.) and 5.06 % ± 0.57 (Mean ± S.E.), while the intra-assay 
CV averaged 13.19% for saliva and 11.71% for serum. Serum P4 showed statistical significance 
with Friedman’s One Way ANOVA (p < 0.0001) but, no significance was noted for the saliva 
samples (p > 0.05). Saliva: Serum ratio was elevated during the follicular phase of the cycle 
(35%), remained between 8 to 12% for the remaining duration of the cycle and showed a 
statistical significance (p > 0.05). As anticipated, there was a significant difference in the serum 
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P4 levels by day of observation in the pregnant mares (p<0.0001). Statistical significance for 
salivary P4 concentration for pregnant mares was seen (p > 0.05), only for days 1 and 3. Sa: Se 
ratio for pregnant mares showed significance (p > 0.05) but with only day 1 contributing to the 
significance. Pearson’s correlation analysis showed that the correlation between salivary and 
serum progesterone levels in cycling mares was not significant except on day 5 for the cycling 
mare group (p >0.05), whereas for pregnant mares only days 5 and 8 (p < 0.05) were seen to 
correlate significantly. The study shows that salivary P4 concentration in mares was not 
statistically correlated with serum values, but nevertheless can be utilized to monitor the luteal 
phase of the estrous cycle as well as for estimating P4 concentrations during early pregnancy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my wife Malavika for always being there. 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ACKNOWLEDGEMENTS 
 
 I am extremely thankful to my advisor, Dr. John Herrmann for not only guiding me 
during my research, but also for all the support he showed during my residency training. He truly 
got me interested in the bovine side of Theriogenology. Many thanks to my advisory committee 
members, Dr. Sauberli, for teaching me the finer nuances of equine reproduction and Dr. Clark 
for her patience and unstinted support during my research and training program. 
And special thanks especially to Dr. Janice Bahr, who students so rightly admire and call 
the RIA Queen. This research would not have been completed without her guidance and her 
generosity.  
 A big thank you to Dr. Yvette Johnson and Dr. San Myint for taking time and helping me 
understand the statistical analysis of my data. 
 I am extremely grateful to Dr. Cliff Shipley for teaching me the importance of being a 
better person first and then a clinician. You are the coolest theriogenologist around!   
A big thanks to the U of I horse barn staff, Dr. Kevin Kline, Ivy Hilliker, Jamie and 
Lacey who so patiently helped me to catch mares in the paddocks during my sample collection. 
It was a wonderful four years working the breeding season with you all. 
Special thanks to Dr. Romana Nowak and her lab, Annie, Fae, Victoriya, Andrea and Jia 
Jia for all their help.  
Most importantly my wife, mother and sister who have always been the source of my 
inspiration, for their love and support.  
vi 
 
TABLE OF CONTENTS 
 
CHAPTER 1: INTRODUCTION………………………………………………………………....1  
CHAPTER 2: LITERATURE REVIEW……………………………………………………….…5  
CHAPTER 3: MATERIALS AND METHODS………………………………………..……….13 
CHAPTER 4: RESULTS……………………………………………………………………..….24 
CHAPTER 5: DISCUSSION…………………………………………………………………….29  
CHAPTER 6: CONCLUSIONS…………………………………………………...…………….33  
CHAPTER 7: TABLES AND FIGURES………………………………………….…………….34  
REFERENCES ...…………………………………………………..……………………………59 
 
 
 
 
 
 
 
1 
 
CHAPTER 1 
INTRODUCTION 
 
Equine reproduction is a highly demanding and performance based field for veterinarians 
due to the limited time available in trying to get the mare bred and in foal as early as possible in 
the breeding season. To meet these demands, veterinarians are largely dependent on various 
diagnostic modalities to accurately assess a mare’s reproductive status, among which trans-rectal 
palpation and ultrasound of the mare’s reproductive tract and immunoassays for various 
reproductive hormones are the most commonly utilized.  
Diagnostic assays of reproductive hormones are usually performed on mares after 
inconclusive findings from genital examination, on irregularly cycling mares or on intractable 
mares to evaluate their reproductive status. Of the reproductive hormones, progesterone (P4) a 
C21 steroid hormone produced primarily by the corpus luteum, is one of the most commonly 
measured hormones  in the field of equine reproduction. It is estimated that as many as 120 
assays for serum P4 are run per day at the BET labs in Kentucky during the peak breeding season 
using radioimmunoassay (RIA) technique (Douglas, 2004). In equines, the plasma P4 
concentrations increase significantly within the first 12 hours (Plotka et al., 1975) and are usually 
greater than 2 ng/ml by 48 hours, post ovulation (Townson et al., 1989; Koskinen et al., 1990). 
P4 concentration continues to rise until it reaches a plateau by around day 6-8 post ovulation 
(Nagy et al., 2004). In non-pregnant mares there is a sharp decrease in plasma P4 beginning by 
around day 14 due to a lack of a maternal recognition of pregnancy factor. However in pregnant 
mares the P4 concentration remains fairly high in serum until the second half of gestation when 
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the feto-placental unit produces a range of 5α-reduced metabolites of progesterone, most notably 
dihydroprogesterone (5α-DHP) and 20α-dihydroxy-5-pregnan-3-one (20α-5P), which 
predominate in the maternal circulation, and P4 itself is barely detectable (Short, 1959;  Holtan et 
al., 1991).  
In routine breeding management of the mare there are a number of clinical applications 
for serial P4 assays which include determination of the adequacy of the corpus luteum in a 
pregnant mare, determination of the day of ovulation, presence or absence of luteal tissue, and 
assessment of the end of seasonal transition (Douglas, 2004). Serial P4 assays are also run on 
mares that are in danger of early or late pregnancy loss or on mares that have a history of 
experiencing early embryonic death and are suspected of suffering from luteal insufficiency.   It 
is due to an often unsubstantiated concern, that thousands of mares are administered exogenous 
progestagens to assuage owner and/or veterinarian fears that a failure of production of sufficient 
endogenous progesterone might cause embryonic or fetal death and abortion (Allen, 2001).  
Serum concentration of P4 from these mares is usually evaluated using an extracted 
radioimmunoassay (RIA) or an enzyme linked immunosorbent assay (ELISA), of which the RIA 
is generally considered as the gold standard in reference laboratories. The use of RIA for serum 
P4 measurement usually involves an extraction process which is both labor intensive and 
biohazardous as it involves use of petroleum ether, methanol, and dry ice that must be used in a 
fume hood. This extraction procedure is required because it has been well documented that in 
species like humans (Tallon et al., 1984) and cows (Kanchev, 1976) more than 80% of 
circulating P4 is bound to plasma proteins and only the free fraction which appears to be 
biologically active (Riad-Fahmy et al., 1982; McGarrigle et al., 1984) is found in saliva. In 
equines, only about 1-3% of P4 in the blood of mares is free (ie. unbound) and the remainder is 
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bound to cortisol binding globulin (CBG) or albumin, which are carrier proteins that interfere 
with the antigen-antibody reaction thus necessitating solvent extraction (Carriere and Lee, 1994). 
Serum proteins like albumin or corticosteroid binding globulin are too large to pass through the 
membranes of the salivary cells. Since 90-99% of steroids in the blood are bound by these 
specific or non-specific proteins, only the free, non-bound steroid molecules are able to pass into 
saliva. Thus salivary concentration of steroid hormones such P4 reflects the free or unbound 
fraction. 
  It has been shown that there is a good correlation between serum and salivary P4 levels, 
and salivary steroid concentrations appear to be closely related to unbound steroid levels in 
serum, which may reflect the biological activity of the hormone (Choe et al., 1983). 
Measurement of salivary P4 concentration appears to be an attractive alternative to serum 
analysis since sample collection is easy and noninvasive and hormone levels in saliva are thought 
to be a better measure of steroid exposure to target organs (Chiappin et al., 2007). The non-
invasive nature and ease of sample collection is especially useful when multiple samples have to 
be collected over a period of time to monitor hormone levels in cases of high risk pregnancies or 
as a part of research studies.  
Measurements of steroid hormones in saliva have been popular in human medicine for 
the past 30 years (Lima et al., 2010).  Since that time its popularity has increased due to the 
attractiveness of non-invasive, repeated and simple stress-free sampling and it has proven to be a 
popular sampling fluid for psychobiology, sports medicine, pharmacology and pediatric studies 
as well as in the area of complementary medicine. In the diagnostic laboratory, salivary P4 and 
estradiol have been used for assessing ovarian function and 17α-OH P4 for the diagnosis of 
congenital adrenal hyperplasia (CAH). In human medicine, salivary cortisol is used for 
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investigating adrenal function and recently there has been considerable interest in the use of 
bedtime salivary cortisol levels as a screening test for Cushing’s disease (Lewis 2006). In 
veterinary medicine, the diagnostic value of saliva as a body fluid has been realized. Studies in a 
wide variety of species ranging from bovine (Kanchev and Stankov, 1988) to the Indian 
rhinoceros (Gómez et al. 2004) have been performed to evaluate the usefulness of salivary 
steroids in the assessment of ovarian function, with encouraging results. In equines, studies 
validating saliva-sampling as noninvasive techniques for cortisol level assessment have been 
performed (Peeters et al. 2011).  However, no validated studies comparing salivary P4 profiles to 
serum levels have yet been published (Douglas, 2004). A quantitative and accurate P4 assay that 
involves the least invasive method of sample collection would be a valuable addition to the 
various commercial assays currently available to the equine industry. Such an assay would 
preclude the need for personnel trained in venipuncture for repeated sample collection and would 
be more receptive to the horse owner or the barn manager.  Thus, the objective of the current 
study was to develop a quantitative, sensitive and specific P4 RIA assay that could be used on 
non-extracted saliva. 
The aims of the study were as follows: 
1. To validate a radioimmunoassay for non-extracted equine salivary P4 
2. To compare and correlate the serum and salivary P4 profiles in cycling mares and mares 
in early gestation (up to day 65). 
3. To evaluate the usefulness of salivary P4 in the identification of the proper stage of 
estrous cycle and pregnancy.  
4. To evaluate if salivary progesterone could replace serum progesterone measurements to 
assess reproductive status in mares. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Endocrinology of the equine estrous cycle and early pregnancy 
Mares are classified as polyestrous long day breeders having an estrous cycle that is 
approximately 21 days in length on an average. The normal length of estrus and the inter-estrous 
interval range from 5 to 7 days and from 14 to 16 days, respectively (Evans et al., 2007). 
Individual variations in estrous cycles exist and can be dependent on seasonal influences, body 
condition, number of follicular waves, lactation, and the possibility of multiple diestrus 
ovulations (Pycock, 2003). During estrus the predominant reproductive steroid in the blood is 
estradiol of the follicular origin, which is primarily responsible for the display of signs of estrus 
by the mare when teased with a stallion. P4 levels are low in the blood at this time (<1 ng/ml). 
However P4 levels have been shown to increase significantly within the first 12 hours of 
ovulation (Plotka et al., 1975) to reach levels more than 2 ng/ml by 48 hours post-ovulation 
(Townson et al., 1989; Koskinen et al., 1990). In fact, Belin et al. (2000) have shown that the 
intra-follicular concentrations of P4 increase as early as about 2 days before ovulation. Mares are 
known to increase levels of P4 secretion in plasma earlier than in any other species and continue 
to rise until day 6 of the cycle when they reach a plateau (Nagy et al., 2004). In cycling non-
pregnant mares, P4 levels rapidly decline after day 14 of the cycle due to lack of maternal 
recognition of pregnancy signal and due to luteolysis associated with peak peripheral blood 
levels of Prostaglandin F2 alpha (PGF2 α) resulting in luteolysis and return to estrus 1 to 3 days 
later.  
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In pregnant mares, the primary CL which develops from the ovulation that led to the 
pregnancy, persists beyond its normal cyclical lifespan of 15-16 days due to the actions of a 
undefined maternal recognition of pregnancy factor secreted by the still spherical (Van Niekerk, 
1965) and still mobile (Ginther, 1983) conceptus. The mare during this period is able to suppress 
the normal cyclical upregulation of oxytocin receptors in the endometrium (Stout et al., 2000) 
and prevent the release of PGF2 α in response to oxytocin released from the endometrium 
(Watson et al., 1997; Stout et al., 2000). Having escaped luteolysis the primary CL persists, but 
also declines in its P4 output over the next 20 or so days, such that the P4 levels may decrease 
from a peak of 12 to 20 ng/ml to as low as 3 to 5 ng/ml (Allen, 2001). The CL then merely exists 
without true LH support till day 38-40 when it is rescued the second time by equine chorionic 
gonadotropin (eCG) produced by the endometrial cups. Due to the LH like action of eCG, 
secondary corpora lutea form on the ovaries resulting in a sharp rise in the P4 values in blood, 
and continue to form until about day 100 -120 of gestation, when the level will typically be as 
high as 25 to 30ng/ml. Between days 40 and 120 of gestation the trophoblast cells, besides 
producing eCG, also acquire a comprehensive repertoire of hormone synthetic capabilities. 
These also include production of P4 and the 5a-reduced metabolites, 5aDHP and 20a-hydroxy-
5a-pregnan-3-one, from around day 70 but utilizing exclusively maternal sources of cholesterol 
(Holtan et al., 1991; Pashen and Allen, 1979). Between days 70 to 150 of gestation in the mare, 
the peripheral blood represents a mixture of P4 of ovarian origin and related progestagens 
secreted by the enlarging allantochorion. Studies by Holtan et al., (1979) have shown that these 
progestagens are sufficient to maintain pregnancy to term even in ovariectomized mares. 
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2.2 Endocrine diagnostics in mares for P4 estimation 
 Mares, more than pregnant females of any other species are administered P4 or progestins 
during part or all of their pregnancy due to fear of luteal insufficiency during pregnancy. 
Pregnancy loss in mares occurs in 10 to 15% during gestation and the majority of these losses 
occur during the first 40 days of pregnancy when the primary CL is the sole source of P4 (Allen, 
2001). It is because of this fear, that it has become common practice for mares bred in the United 
States and several other countries to receive P4 or synthetic progestagens early in the 
postovulatory period, especially in mares with a history of early embryonic loss or after embryo 
transfer. Mean serum P4 concentrations of 4 ng/mL or greater are considered necessary to 
maintain pregnancy consistently in mares (Shideler et al., 1981). P4 is by far the most common 
reproductive hormone assayed in broodmare practice. Because of the physiological patterns of 
change in P4 and progestagen concentrations during gestation, single-point measurements of 
either hormone are not necessarily helpful and serial sampling for determination of trends or 
mean concentrations during a given interval is recommended (Troedsson, 2003). The most 
common endocrine assays used for the purpose are RIA and ELISA which are highly specific for 
P4, whereas others (competitive protein binding) reflect total progestagen concentration. The 
most common assay used for P4 estimation is the RIA as it can measure extremely small 
quantities with greater accuracy. Allen et al., (1974) and Sato K. et al.,  (1977) have provided 
reference ranges for P4 in cycling and non-cycling mares as well as relationship of P4 with 
estradiol during the estrous cycle. In 1980, Gunther et al. experimented to measure and compare 
P4 in the milk and plasma of mares using RIA in order to try and establish an alternative test for 
pregnancy diagnosis in mares and concluded that milk could indeed be used by day 18 
conclusively to differentiate pregnant and non-pregnant mares. Since then various quantitative 
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and qualitative ELISA (EIA) tests have been evaluated to measure P4 in serum and plasma of 
mares with the aim of providing a rapid and reliable P4 estimation. In the mare, values obtained 
with quantitative ELISA are usually greater than values with RIA, but the two assays show 
similar profiles for plasma progesterone concentration (Giguere, 1994). Correlation between the 
two types of assay is high (coefficient of correlation = 0.94), especially for the detection of the 
low concentrations of progesterone found during estrus and the subsequent rise during the luteal 
phase of the cycle (Eckersall et al., 1987). A recent study by Relave et al., (2007) also has shown 
that a semi-quantitative EIA that they developed was a comparable and reliable test to RIA and 
chemiluminescent assays for measuring P4 in the blood of mares. In spite of these various 
studies, no quantitative EIA commercial kits capable of measuring extremely minute quantities 
of P4 are available in the market and hence reference laboratories still continue to use solid phase 
RIA kits developed for humans as a reliable assay for monitoring P4 in mares. 
 
2.3 Saliva, an alternative to serum/plasma for P4 estimation.  
Salivary analysis has become an important resource for the evaluation of salivary 
conditions with physiologic and pathologic implications and is a useful tool for disease 
diagnosis, mainly due to its origin, composition, functions, and interactions with other organ 
systems (Chiappin et al., 2007). Additionally, it is a simple and non-invasive collection method, 
easy to store, and is inexpensive when compared to blood collection. With the addition of 
modern techniques and chemical instrumentation equipment, there has recently been an increase 
in its use for laboratory investigations, applications for basic and clinical purposes in dentistry 
and other medical areas. Oral fluid sampling is safe for the operator and the patient, and has easy 
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and low-cost storage. These characteristics make it possible to monitor several biomarkers in 
infants, children, elderly and uncooperative subjects, and in many circumstances in which blood 
and urine sampling is not available. Saliva analyses have been used mainly in dentistry and for 
studies in oral diseases to help assess the risk of caries, by measuring saliva buffer capacity and 
bacterial contents (Van Nieuw Amerongen et al., 2004). Oral fluid is mainly utilized for research 
and diagnostic purposes concerning systemic diseases that involve the salivary glands and oral 
cavity, such as Sjögren syndrome (Pedersen et al., 2005) Beçhet syndrome, benignant and 
malignant oral tumors (Li et al., 2004). Studies that use saliva for the diagnosis of HIV using 
specific antibodies as biological markers (Holm et al., 1993; Burgess-Casseler et al., 1996) have 
been demonstrated to be successful and reproducible. This method made the first quick test for 
the detection of HIV-1 infection possible, a test that the US Centers for Disease Control and 
Prevention (CDC) has been using a saliva-based test for the detection of HIV that provides 
results in only 20 minutes (Burgess-Casseler et al., 1996).  . 
Saliva is used for the detection of different biomarkers such as electrolytes, hormones, 
drugs and antibodies in human and veterinary medicine. The measurement of steroid hormones 
in saliva is a widely accepted alternative to the determination in plasma or serum (Riad-Fahmy et 
al., 1982). Salivary steroids correlate very well with the non-protein-bound fraction in plasma 
samples (Vining et al., 1987). Thus saliva can be analyzed as a part of evaluation of endocrine 
function. The majority of hormones enter saliva by passive diffusion across the acinar cells. Most 
of these hormones are lipid-soluble (i.e., steroids). Small polar molecules do not readily diffuse 
across cells and instead enter saliva through the tight junctions between cells via ultrafiltration 
(Quissell, 1993; Read, 1993). The molecular-weight cut-off for ultrafiltration is 100-200, which 
prevents many hormones from entering saliva from serum by means of ultrafiltration. In 
10 
 
addition, active transport does not appear to facilitate hormone transfer into saliva (Vining and 
McGinley, 1986). For neutral steroids which diffuse readily into saliva, salivary hormone levels 
represent the non-protein-bound (free) serum hormone levels. In contrast due to their size, 
protein hormones do not enter saliva through passive diffusion, but primarily through 
contamination from serum as a result of outflow of gingival crevicular fluid (GCF) or from oral 
wounds. In blood 95-99% of the steroids are bound up by binding proteins such as sex hormone 
binding globulin (SHBG), cortisol binding globulin (CBG), and albumin. The remaining 
unbound fraction (1-5%) is referred to as “free” hormone, and is generally regarded as 
bioavailable, since steroid hormone molecules must interact with sites on DNA unencumbered 
by binding proteins. Saliva hormone levels are inherently more reflective of bioavailability no 
matter which hormone delivery mode is used, because the salivary hormones represent hormone 
that has been delivered to tissue (Lima et al., 2010).  
One of the most common assays used in humans is 17a-hydroxyprogesterone (17P) in 
serial saliva samples for the diagnosis and treatment monitoring of congenital adrenal 
hyperplasia. Likewise, serial salivary progesterone analysis to monitor ovarian function in 
subfertile women has also been a popular application since P4 values do not fluctuate with the 
circadian rhythms, enabling sampling at different times of the day possible. Salivary 
progesterone measurement can be used for longitudinal monitoring of luteal function (Lipson et 
al., 1994), as it displays both free and total serum progesterone levels during normal menstrual 
cycle and in pregnancy. Vimpeli et al., (2001) evaluated salivary P4 levels during two luteal 
support treatment regimens for in-vitro fertilization (IVF) in humans. Serum progesterone levels 
were significantly lower in patients who received vaginal progesterone than in those who 
received Human Chorionic Gonadotropin (hCG). But this group also had high salivary P4 
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concentrations suggesting that vaginally administered progesterone might have extraordinary 
pharmacokinetics compared with other administration routes. Efforts have been made in human 
medicine to validate and establish cutoff levels for P4 in saliva during the follicular and luteal 
phases of the menstrual cycle. Ishikawa et al., (2002) have suggested such cutoff values for P4 
during the mid-luteal stage of the cycle and have recommended daily salivary progesterone 
profiles during the luteal phase and a simple estimation of mid-luteal salivary progesterone 
useful for the diagnosis of luteal phase defects. In addition, several studies reported that a good 
correlation exists between the plasma and salivary concentrations of progesterone, since salivary 
progesterone is thought to reflect the levels of free serum progesterone (Walker R.F. 1985; Choe 
et al., 1983; Tallon et al., 1984; Ellison et al., 1993). Thus, salivary progesterone measurements 
can provide a practical way of allowing longitudinal studies of the corpus luteum function. 
 
2.4 Applications of salivary P4 estimation in veterinary medicine 
 Studies on use of salivary assays for hormonal estimation in veterinary medicine have 
been very limited and have generally focused on its use in early pregnancy diagnosis for farm 
animals. Kanchev et al., (1988) attempted to set up a simple, sensitive and reproducible direct 
RIA method for the determination P4 in bovine saliva for the assessment of the ovarian function 
and early pregnancy diagnosis in cows and heifers. They found that salivary levels measured by 
this method reflected changes in plasma progesterone concentrations. The saliva/plasma 
progesterone ratio X 100 during the follicular phase was 15% while during the luteal phase it 
was 12%. The assay was sensitive enough to differentiate non-pregnant animals from pregnant 
ones. In the same year a comparative study between P4 concentrations in plasma, milk and saliva 
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of cows in different reproductive stages was conducted (Gao et al., 1988) showing that salivary 
progesterone could be used to assess ovarian function in cows and that the salivary progesterone 
concentrations in the luteal phase and during pregnancy reflected the plasma concentrations more 
closely than the values obtained in milk. Applications of salivary P4 assays have also been 
employed in the swine industry. Moriyoshi et al., (1996) tried validating a P4 salivary assay 
using bovine milk P4 EIA kits and managed to prove that qualitative measure of salivary P4 
could be a practical method of diagnosing early pregnancy in sows. Likewise Needham et al. 
(2007) have demonstrated that similar results can be obtained in sheep as well. There are also 
unpublished references to measurement of salivary P4 in horses (Smith, 2005) using milk P4 
EIA kits.  
 Due to the ease and non-invasive nature of sample collection salivary P4 measurement 
has been found to be useful in captive wild animal species such as the Black Rhinoceros 
(Czekala et al., 1996). Using RIA and High Performance Liquid Chromatography (HPLC) it was 
possible to measure salivary estradiol and 20 alphahydroxypreg-4-en-3-ones in diagnosing 
pregnancy and even predicting impending parturition. Based on the same study, ovarian cycles 
were monitored in the Indian Rhinoceros at the National Zoo using salivary steroids (Gomez et 
al., 2004).  Analyses of salivary androgens, progestins and estrogens were found to reliably 
monitor follicular activity. Salivary P4 estimation in marine mammal species such as captive 
false killer whales (Atkinson et al., 1999) and Hawaiian Monk Seal (Pietraszek et. al., 1994) 
have shown that salivary concentrations of estrogen and progesterone may provide an accurate, 
less-invasive method of monitoring reproductive hormones. In equines, no published data 
providing detailed information of P4 measurements in saliva is available to date, though salivary 
cortisol measurements are fast gaining popularity.  
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Objectives 
The study was conducted to evaluate whether salivary levels of P4 in mares could be 
used to identify the stage of their reproductive status. RIA’-s were set up to compare the serum 
and salivary P4 profiles collected at selected days of the estrous cycle of non-pregnant cycling 
mares and during early gestation of pregnant mares. Hypothesis one was that the levels of P4 in 
saliva would rise and fall concurrently along with levels in the serum during the selected days of 
the estrous cycle and during early pregnancy of these mares. Hypothesis two was that the 
salivary P4 levels would be consistently in the range of 1 to 5 % of the levels found in serum and 
that these findings would prove that saliva could be a useful alternative to serum in monitoring 
P4 profiles in mares.  
 
3.2 Selection of Animals for the Study 
Fifteen Standardbred mares included in the study were obtained from the University of 
Illinois Horse Farm and were divided in two groups; non-pregnant cycling (8 mares) and 
pregnant (7 mares). The study was conducted during the breeding season of 2011 and the serum 
and saliva samples were obtained between the months of June and September. Mares were 
selected randomly and their ages ranged between 4 to 16 years. Prior to sample collection, the 
reproductive tract of each non-pregnant mare was palpated trans-rectally using manual and 
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ultrasound techniques and the mare was selected for the study only if she displayed signs of 
cyclicity. This included evidence of growth of multiple follicles with at least one follicle greater 
than 35 mm in diameter, signs of uterine edema, receptivity upon teasing with a stallion, and also 
presence of  corpora hemorrhagica (CH) or corpora lutea (CL) on the ovary indicating a previous 
ovulation. Mares selected for the pregnant group were bred with semen from stallions housed at 
the same farm by artificial insemination technique. Pregnant mares were identified by examining 
them with a trans-rectal ultrasound on day 14 post-ovulation and identifying an embryonic 
vesicle in the reproductive tract.  
 
3.3 Sample Collection and Initial Processing 
Serum and saliva samples were collected from each mare included in the study on 
different days of the estrous cycle and early pregnancy at the same time of the day 
(approximately 10:00 a.m.)  to avoid any effects of the circadian rhythm on the hormone profiles. 
Blood (10 ml) was drawn from the left jugular vein of each mare in a red top BD Vacutainer® 
blood collection tube  with a conventional stopper, using a BD Vacutainer® 21 G x 0.75 inch 
needle and holder (Becton Dickinson Blood Collection Products, NJ USA 07417). The tubes 
were centrifuged at 2000 x G rpm for 10 minutes within 2 hours of collection to separate the 
serum. The serum was transferred to separate 5ml Snap Cap Falcon tubes (BD Biosciences, MA 
01730 USA) and then stored at -20⁰C until further processing.  
Saliva samples were collected from individual mares immediately after collection of the blood 
sample. A 7.5 ml capacity plastic transfer pipette (Cole-Palmer Disposable Transfer Pipettes, IL 
60061 USA)   was used for saliva collection. The procedure involved proper restraint of the head 
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of the mare and collection of the pooled saliva from the buccal commissures by aspiration with 
the pipette. In cases where sufficient saliva was not obtained, secretion was stimulated by 
offering feed such as alfalfa hay, and then collecting the samples after the mare had finished 
chewing and the mouth was relatively free of feed material. All samples were transferred from 
the collecting pipette to a standard red top vacutainer sterile blood collection tube (Becton 
Dickinson Blood Collection Products, NJ USA 07417). Every effort was made to collect as much 
saliva with minimal feed or blood contamination. Saliva was then frozen at -20⁰C and were 
subjected to four freeze-thaw cycles which helped in degradation of mucins present in saliva and 
allowed a cleaner separation of the aqueous phase. The sample was centrifuged to precipitate any 
particulate matter, and the supernatant was then transferred to a red top blood collection tube and 
stored at -20⁰C.  
Saliva and serum samples were collected from the cycling and pregnant mares on various days of 
the estrous cycle and early gestation (up to day 65). The collection time-points are as shown in 
Table 1 and Table 2. 
 
3.4 Preparation of Reagents for the Radioimmunoassay 
1) Phosphate Buffered Saline 0.01 M (PBS) 
The following reagents were measured and added to Distilled Water:  
- 1.3 g sodium phosphate, monobasic (NaH2PO4-H2O)* 
- 10.85 g sodium Phosphate, dibasic (Na2HPO4-7H20)* 
- 42.5 g sodium Chloride (NaCl)* 
- 5 liters of distilled water 
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*(Fisher Chemicals, Fisher Scientific NJ 07410) 
2) 0.1% PBS Gelatin 
The following reagents were added to 1 liter of PBS (0.01M) to prepare PBS Gelatin (PBS-Gel) 
- 1 g gelatin (Bio-Rad laboratories, Richmond, CA 94804) 
- Heat to boiling to dissolve the gelatin 
- Add 0.1 g of Na azide (ACROS, NJ, USA) to the solution and keep in the cold room 
(4⁰C) overnight at all times. 
3) Charcoal Dextran 
To 500 ml of 0.01 M PBS the following were measured and added: 
- 3.5 g of charcoal (Sigma Chemical Co. St. Louis, MO 63103) 
- 0.35 g dextran (Sigma Chemical Co. St. Louis, MO 63103) 
- Stir for 1 hour before use and store at 4⁰C up to one month. 
4) Preparation of Tracer 
For preparation of the tracer, Tritiated 3H-Progesterone (3HP4) (250 mCu/ 250 µl, Perkin-
Elmer, Boston, MA 02118) was used. This isotope was diluted with absolute alcohol to make 
the stock solution. Original isotope was removed from the freezer and brought to room 
temperature and 100µl of the isotope were added to 0.9 ml of absolute alcohol (stock solution). 
Next, 40 µl of this stock solution were added to 20 ml of PBS-Gel to make the tracer for RIA 
assays. This solution was mixed well and counted in the liquid scintillation counter after 
addition of 3 ml of scintillation fluid. The final counts desired were 10,000 count per minute 
(cpm)/100 µl. This solution was then stored in the cold room for overnight incubation and 
future use. A RIA assay was set up to evaluate the binding efficiency which should be close to 
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40% percent binding (Table 3). The calculations for binding efficiency were calculated as 
follows: 
Percent Binding = Bound (Bo) cpm – Non-specific Binding   x 100 
                                        Total cpm – Non-specific Binding 
5) Preparation of the Spike  
 Spike (3HP4) was prepared by adding 9 ml of PBS-Gel to 1ml of the prepared tracer (10,000 
cpm/100 µl) to give a radioactivity of 1000 cpm/100 µl. The spike so prepared was mixed gently 
and kept in the cold room for overnight incubation and future use. The spike was used as a 
known source of radioactivity which was added to the serum samples before the solvent 
extraction process and to the hot recovery vials to account for procedural losses during 
extraction. 
6) Preparation of the P4 Antibody 
 A P4 antibody validated and prepared at the Animal Sciences Department, University of 
Illinois at Urbana-Champaign (UIUC) was graciously provided by Dr. Janice Bahr’s laboratory. 
This P4 antibody (GS #253), generated against preogesterone-11-hemisuccinate: bovine serum 
progesterone cross-reacts 22% with 11 α-hydroxy-progesterone, 4% with 5 α-pregnane-20-dione, 
2% with 17 α-hydroxy-progesterone and <0.1% with Testosterone and Estradiol. 
7) Preparation of Standards 
 P4 standards of various concentrations were prepared, and were used for determination of the 
standard curve as well as for assay validation. Based on the results obtained after determination 
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of the standard curve the sensitivity of the assay was calculated and standards falling on the 
linear part of the standard curve were used for the estimating P4 in serum and saliva samples. 
Table 4 shows the different concentrations and dilutions used to prepare the standards.  
 
3.5 Validation of the Radioimmunoassay  
1) Determination of a Standard Curve 
 A P4 standard curve was validated by using increasing known amounts of unlabeled antigen 
(P4 standards as prepared above) and constant amounts of antiserum (P4 antibody) and labeled 
antigen (3H-Progesterone). Thus various concentrations of unlabeled antigen were reacted with 
constant amounts of antiserum and the labeled antigen to obtain a sigmoid curve after running 
the values in universal computerized assay calculator software AssayZap. The linear portion of 
the curve was identified the only valid part of the curve. The values falling on the flat part at the 
beginning and end of the curve were rejected as these values are usually subject to large errors 
and are not very reproducible with greater than 10% variability. Thus the range of the standard 
curve was determined by identifying the 80% and 20 % bound values and accepting values 
falling between these two points. As a general rule the standard curve should have at least five 
points which fall on the linear part of the curve (Refer to Fig. 1). The RIA for the standard curve 
was set up in the following manner. 
Day 1 
 Twenty two 12 x 75 mm culture tubes (Fisher Brand Disposable Culture Glass Tubes, NJ, 
USA) were numbered and labeled as outlined in Table 5. The amount of standard, PBS-Gel, P4-
antibody (P4-Ab) and the labeled antigen 3H-P4 were added to the tubes using a Repeating 
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Pipetter (Fisher Brand NJ, USA) to minimize error during pipetting. The tubes were then 
vortexed to ensure thorough mixing and were incubated at 4⁰C in the cold room overnight for 
equilibration.  
Day 2 
 Before carrying out the separation of bound and free steroid, the charcoal dextran solution 
was subjected to at least 30 minutes of stirring on a magnetic stirrer to ensure thorough mixing. 
200 µl of charcoal dextran solution was added to the tubes (except tube no. 3 and 4 which 
represented the Total amount of labeled radioactivity). The tubes were vortexed gently to ensure 
thorough mixing and were incubated in the cold room for 15 minutes at 4⁰C to ensure proper 
separation of the unbound fraction of steroids by the charcoal dextran and the tubes were then 
centrifuged in a refrigerated centrifuge (Beckman Model J-6B, Beckman-Coulter Inc. CA, USA) 
at 4⁰C and 3000 X G RPM for 10 minutes. Using a Digiflex CX Automatic Pipette (Micromedic 
Systems Inc., Seattle WA) 300 µl of the clear supernatant was aspirated and transferred to plastic 
scintillation vials (Fisher Brand, Fisher Scientific, NJ) and 3ml of Scintiverse ™ BD Cocktail 
(SX18-4) (Fisher Scientific, NJ) were added. The vials were capped, thoroughly shaken to mix 
the contents and placed in a Liquid Scintillation Analyzer Tri-Carb 2200 CA (Packard 
Instrument Co. CT 06450, USA) to determine the radioactivity in cpm. The readings (in cpm) 
were then analyzed using a universal computerized assay calculator software AssayZap v.3 1 
(Copyright® Biosoft & PL Taylor, Cambridge, UK). 
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2) Validation for parallelism and recovery of unlabeled ligand (cold recovery) for serum 
samples 
 There are two critical validation steps. First, it is necessary to determine that the volume of 
the sample does not affect the amount of hormone measured. In other words if, 50, 100 or 200  
µl (or more) are assayed the final concentration of hormone (in pg/ml or ng/ml) is the same in 
each sample when expressed per ml. This step is also done in order to determine that non-
specific materials in the sample did not interfere with the accurate determination of the sample. 
The presence of interfering substances such as fat or cholesterol in the sample can result in 
measurement of lesser hormone as the sample volume is increased. A pooled serum sample was 
used for the assay, prepared by mixing 100 µl of serum of the seven pregnant mares from day 35 
of gestation, as by this day the P4 levels in the mare’s blood would theoretically be high enough 
to be detectable easily by the assay. Four different volumes of the sample tested for parallelism 
were 50 µl, 100 µl, 200 µl and 300 µl.  
 Validation of cold recovery was done by measuring known amounts of unlabeled ligand 
(cold hormone) added to the samples before extraction. The percent of the unlabeled ligand 
recovered would be indicative of the percent endogenous hormone measured. Thus three 
different amounts of unlabeled ligand (in pg) were added to 100 µl of sample in separate tubes 
viz. 50 pg, 100 pg, and 200 pg.  
 A set of internal controls using 125 and 250 pg standards were included in the assay to 
determine the inter-assay coefficient of variability. All standards and samples and internal 
control tubes were run in duplicates.  
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Step 1: Solvent Extraction 
  The serum samples were subjected to solvent extraction procedure to dissociate the P4 in the 
sample from the binding proteins and dissolve it in the organic solvent. A starting volume of 500 
µl of each sample to be tested for parallelism was pipetted into in 16 x 100 mm disposable 
culture glass tubes (Fisher Brand Disposable Culture Glass Tubes, NJ, USA). To each sample 
tube, 100 µl of the spike (1000 cpm/100 µl) were added to account for procedural losses. In 
addition, 100 µl of the spike were added to two scintillation minivials which were used as Spike 
controls in the RIA.  The samples remained at room temperature for 1 hour before starting the 
extraction process. 6ml (approximately 10 times the serum sample volume) of petroleum ether (E 
120-4) Optima ® (Fisher Scientific, NJ) were added to the each sample. The samples were then 
agitated vigorously in a multi-vortexer for 10 minutes inside a fume hood. The aqueous phase in 
each sample was frozen with methanol and dry ice and the organic phase containing the steroids 
was decanted into new 12 x 75 mm disposable culture glass tubes. These were then placed in a 
hot water bath (40⁰C) inside the fume hood and the organic solvent was evaporated by gentle 
flow of air. After the organic solvent was evaporated, the sides of the tubes were washed several 
times with petroleum ether and again evaporated. After complete evaporation an equal amount of 
PBS-Gel (500 µl) was added to each tube and was vortexed for 1 minute. The samples were 
incubated overnight at 4 ⁰C in a cold room. 
Step 2: Setting up the RIA 
 Before setting up the RIA on Day 2, 1/5th (100 µl) of the original sample was transferred to a 
minivial to account for hot recovery, to which 3ml of scintillation fluid were added. The cpm in 
the sample when compared to cpm of the hot recovery minivials will indicate the percent of 
sample recovered. The RIA was set up in a similar fashion as the set up for standard curve. The 
22 
 
assay plot for the RIA is displayed as Table 6. After adding the reagents the tubes were then 
vortexed to ensure thorough mixing and were incubated at 4⁰C in the cold room overnight for 
equilibration. 
Step 3 Charcoal Dextran Separation.  
 The separation of bound and free steroid with charcoal dextran solution and the estimation of 
radioactivity on the Liquid Scintillation counter were performed as described previously.  
3) Validation for parallelism and recovery of unlabeled ligand (cold recovery) for saliva samples 
 The procedure for validation of the saliva samples was carried out in a similar manner to that 
of the serum. The pooled saliva sample assayed was from mares at 65 days of gestation because 
of limited volume of saliva samples available at day 35. An experiment was conducted to 
evaluate the difference in recoveries with and without subjecting the saliva to the solvent 
extraction process. Based on the results it was decided that the saliva samples need not be 
extracted as these gave better estimation of the P4.  Also there was no need for estimating the hot 
recoveries. This confirmed the hypothesis that the P4 in saliva represents the free (unbound) 
fraction found in the body and hence does not require extraction. 
 
3.6 Estimation of progesterone in serum and saliva samples 
 Upon validation of the respective assays, the actual serum and saliva samples were run in a 
similar fashion. The samples were run in triplicates and as before internal controls were 
maintained for evaluation of intra- and inter-assay coefficients of variation. The serum P4 
values obtained on AssayZap were corrected for hot recovery in the following example: 
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Spike cpm = 978 cpm. 1/5th of 978 = 978/5 = 195.6 
For Sample X: Hot Recovery (cpm) = 164 
Hence,    164 x 100_ =    83.84 % 
                 195.6 
Mean Result of Sample X (pg) = 35.65  
Corrected result for Sample X = 35.65 x 100 =  
                                                         83.84    
This is the corrected value after accounting for the hot recovery. 
 
3.7 Statistical analysis 
 Statistical analysis was conducted using IBM SPSS Statistics Desktop software version 
20.0.0.  Friedman’s non-parametric one-way analysis of variance was used to identify 
differences in serum P4 concentration over time, salivary P4 level over time, and the ratio of 
salivary to serum P4 concentration over time in the two groups of mares (pregnant and open).  
Post-hoc pairwise comparisons of each sampling period were conducted using the Wilcoxon-
Signed Ranks test.  To assess the correlation between serum P4 levels and salivary P4 
concentration Pearson’s Correlation Analysis was conducted using the Proc Corr statement of 
SAS 9.2 software (SAS Institute Incorporated).  
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CHAPTER 4 
RESULTS 
 
Validation of the Standard Curve. 
The standard curve generated had a sigmoid shape with five standards ranging from 32 
pg to 500 pg (Figure 1) fitting on the linear part of the curve. The lowest concentration that the 
assay could detect was 16 pg which still fell on the upper flat part of the slope. The curve wasn’t 
sensitive enough to detect standards 4 pg and 8 pg consistently as these were shown out of range. 
Hence it was decided to omit these standards in the subsequent assays and only keep the 
standards that range between 16 to 1000 pg, which was satisfactory because the expected P4 
range in serum and saliva was expected to range between approximately 50 pg/ml and 10 ng/ml. 
The curve had an overall good quality of fit (R²= 0.999905). The percent binding was close to 
40% as desired (42.64%) and the non-specific binding was quite low (1.86%). The calculated 
means for the standards were close to the estimated values indicating a very low pipetting error 
and high specificity of the assy. The values are shown in Table 7. 
 
Validation for Parallelism and Recovery of the Unlabeled Ligand (cold recovery) for serum. 
Parallelism for the pooled serum sample was performed to determine that non-specific 
materials in the sample did not interfere with the accurate determination of the sample. Four 
different volumes (50 µl, 100 µl, 200 µl and 300 µl) had been assayed and the cpm obtained was 
entered into the AssayZap program to determine if the P4 concentration in each sample showed a 
proportionate increase. The recovery from the 100 µl was 99.5 pg. Likewise the values obtained 
from 50, 200 and 300 µl were 44 pg, 212 pg and 286 pg The same assay had also been set up for 
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the recovery of the cold or unlabeled ligand and three different amounts of unlabeled ligand (in 
pg) were added to 100 µl of sample in separate tubes viz. 50 pg, 100 pg, and 200 pg. The 
recovery for these different amounts was 132 pg (88.29%), 211 pg (105.76%) and 306 pg 
(102.17%).  
 
Validation for Parallelism and Recovery of the Unlabeled Ligand (Cold Recovery) for Saliva 
Samples.  
Saliva samples were assayed without extraction with petroleum ether. This change in 
procedure was based on the fact that after running an extracted vs. non-extracted sample, it was 
observed that the hormone estimation without extraction of saliva was almost 25 % more than 
that of extracted sample. The increasing volumes (50 µl, 100 µl, 200 µl and 300 µl) used for 
parallelism gave proportionate recoveries at 35.5 pg, 72.0 pg, 138.2 pg, and 208.4 pg. Cold 
recoveries for saliva samples assayed also showed a proportionate recovery at 118.4 pg 
(96.33%), 181.09 pg (104.73%), and 289.41pg (106.04%) for the 50, 100 and 200 pg added to 
100 µl of saliva sample.  
 
Validation for Hot Recovery for Serum 
Hot recoveries were estimated to account for the procedural losses that could occur 
during the extraction process. The spike containing a known amount of radioactivity (3H-P4; 
1000 cpm) was added to the serum samples before the solvent extraction process and 1/5 of this 
original amount (500 µl) was transferred to a scintillation vial after the extraction process was 
over. The average percent hot recovery obtained after extraction was 86.22 ± 0.65 (Mean ± S.E.). 
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Inter-assay and Intra-assay Coefficients of Variation 
To express the precision, or repeatability, of the radioimmunoassay test results two 
measures of the Coefficient of Variability (CV: the Inter‐Assay CV and the Intra‐Assay CV) 
were measured. The inter-assay CV for the low and high internal controls was 6.91% ± 0.81 
(Mean ± S.E.) and 5.06 % ± 0.57 (Mean ± S.E.). Likewise the intra-assay CV was calculated for 
all assays and averaged to 13.19 % and 11.71%, respectively, for saliva and serum. 
 
Progesterone Profiles in Serum of Cycling Mares 
Serum P4 concentrations in cycling mares averaged 1.52 ng/ml on day 1 post ovulation 
and rose steadily to peak at day 8 of the cycle at 9.06 ng/ml. The serum P4 concentrations then 
steadily decreased by day 14 and fell sharply by day 17 post ovulation and reached baseline 
levels again by day 20 (1.40 ng/ml). Friedman’s non-parametric one-way analysis of variance 
revealed significant differences in serum P4 levels by day of observation (Friedman’s Chi-
Square=47.37 p<0.0001). A Wilcoxon Signed Rank Test revealed significance between all days 
except days 17 and 20. The test statistics and the rank tests are as shown in Table 8. i) to vi).  
 
Progesterone Profiles in Saliva of Cycling Mares      
The P4 levels in the saliva of cycling mares rose proportionately to the rise in the serum 
levels as the estrous cycle progressed. Saliva P4 concentrations also peaked by day 8 of the cycle 
(Avg. 0.76 ng/ml) and then fell steadily as the serum levels also decreased post day 14 of the 
cycle. However salivary P4 as a percentage of serum P4 levels did not follow this general 
pattern. Salivary P4 concentration was at its peak at the beginning of the cycle (35%) and then 
fell sharply by day 3. The proportional percentage then remained between 8 to 12 % between 
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days 3 and 14 post ovulation and then rose sharply again by day 17 (29.98%) and peaked again 
by day 20. Table 9 shows comparative serum and salivary P4 levels and the ratio of saliva: serum 
in cycling mares. Figure 2 is a graphical representation of P4 profiles in serum and saliva of 
cycling mares. 
Friedman’s one way ANOVA showed no significant difference in salivary P4 levels by 
day of observation (Friedman’s Chi-Square = 8.46, p = 0.206).  
A significant difference was however seen with the saliva to serum ratio in cycling mares 
(Friedman’s Chi-Square = 28.82 p<0.0001) as seen in Figure 4. Table 10 i) to iv) shows the 
pairwise comparisons.  
 
Progesterone Profiles in the Serum of Pregnant Mares 
Progesterone levels in pregnant mares rose sharply after ovulation, peaked around day 8 
(7.85 ng/ml), decreased slightly by day 25, but again started rising post day 35 of gestation and 
remained constant till day 65. The percent P4 levels in saliva as compared to serum were high 
(24.13%) immediately after ovulation but fell sharply by day 3 post-ovulation and were 
maintained in a steady range between 8 to 11% till day 65 of gestation. As anticipated, there was 
a significant difference in the serum P4 levels by day of observation in the pregnant mares 
(Friedman’s Chi-Square = 47.60, p<0.0001). Besides, the post-hoc pairwise comparison of each 
sampling period also showed significance for almost all sampling days. Table 11 i) to viii) shows 
the Chi-Square values and the Wilcoxon Signed Rank Values for serum P4 concentrations in 
pregnant mares. Figure 3 is a graphical representation of P4 profiles in serum and saliva of 
cycling mares. 
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Progesterone Profiles in Saliva of Pregnant Mares 
Progesterone levels in the pregnant mare saliva rose concurrently along with serum levels 
and peaked at day 8 similar to serum values. Levels were maintained consistently above 0.5 
ng/ml past day 14 up to day 65. Percent P4 in saliva compared to serum was approximately 25% 
(24.13%) on day 1 post ovulation and then values dropped sharply and were maintained between 
8 to 11% till the last day of sample collection. Figure 3 is a graphical representation of P4 
profiles in serum and saliva of pregnant mares along with table showing the days of significance. 
Statistical significance was seen after Friedman’s one way ANOVA, however only days 
1 and 3 seemed to contribute to this significance. Table 12. i) to iii) shows values for the 
Friedman’s one way analysis and Wilcoxon Signed Ranks for day 1 and 3. 
Ratios of saliva: serum P4 concentrations in pregnant mare’s shows statistical 
significance however the Wilcoxon Signed Ranks Test showed that only day 1, serum: saliva P4 
concentration ratio was of significance (Figure 5). Table 13 shows the values for the serum: 
saliva ratio for pregnant mares. 
 
Pearson’s Correlation Analysis 
Pearson’s correlation analysis showed that the correlation between salivary and serum 
progesterone levels in cycling mares was not significant except for day 5 of the cycle (r = 0.784, 
p-value = 0.021). Likewise, there was no significant correlation found in the pregnant mare 
group as well except for days 5 (r = 0.959, p-value = 0.0006) and 8 (r = 0.771, 0.042) which 
showed a strong positive correlation. Table 14 shows detailed results of the analysis.  
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CHAPTER 5 
DISCUSSION 
 
The present study evaluated whether salivary levels of Progesterone (P4) in mares could be 
used to identify the stage of their estrous cycle and to differentiate non-pregnant and pregnant 
animals. As per the authors knowledge this is the first attempt to validate and compare salivary 
P4 to serum concentration in cycling and pregnant mares using RIA.  Based on the results and 
statistical analysis of the data the following findings were considered important: 
1) Overall, salivary P4 values were not found to be of statistical significance nor did they 
correlate significantly with serum P4 values. 
2) During the estrous cycle salivary P4 values as a percentage of serum levels were seen to 
be much higher immediately post-ovulation in cycling mares, after which they fell and 
were maintained within a consistent range. Salivary P4 concentrations increased again 
towards the end of the cycle as the mares entered their follicular phase of the cycle. 
3) On day 1 post ovulation salivary P4 values as a percentage of serum levels, in pregnant 
mares. These values then declined sharply and were again maintained within a consistent 
range till day 65 which was the last day of sample collection. 
4) The study demonstrated that salivary P4 can be estimated by Radioimmunoassay (RIA) 
using a non-extracted (neat) saliva sample.  
5) The study is first of its kind and the findings could be used as a benchmark for further 
studies in the area. 
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Serum P4 values in cycling and pregnant mares have been studied since 1970’s. Serum P4 
concentrations in both cycling and pregnant mares in this study rose rapidly after ovulation with 
levels well above 2ng/ml by day 3, and peaked by day 8 for both cycling and pregnant mares (8.1 
ng/ml and 7.8 ng/ml). In cycling mares, these levels plateaued till day 14 after which a sharp 
decline was seen in serum P4 levels. These measurements are in accordance with the findings 
published in previous studies (Allen, 1984). The sharp decline after day 14 is due to a lack of 
maternal recognition of pregnancy factor, which if present would prolong the lifespan of the 
corpus luteum. By day 17 serum P4 levels had decreased below 2 ng/ml as the mares entered the 
follicular phase of the estrous cycle. The last day of sampling for the non-pregnant cycling mare 
group was day 20±1. By this time most mares had ovulated again and resumed their next cycle, 
and the P4 levels had started rising again. In the pregnant mare group, the P4 levels were 
maintained and reached a plateau past day 14 of gestation. P4 levels in this group in fact declined 
slightly after day 14 but were maintained above 4 ng/ml. The P4 levels then rose again to plateau 
past day 35 of gestation. These findings reflect the decline in secretory activity of the corpus 
luteum from as early as day 14-16 (also seen in pregnant mares) and rescue of the pregnancy by 
formation of secondary corpora lutea between 35 to 45 days of gestation (Allen, 1984).  
When salivary P4 levels were compared to the serum P4 levels, no significant correlation 
was found between them, except on day 5 in pregnant and cycling groups and day 8 in the 
pregnant mare group only. These findings are contrary to studies in humans (Walker et al. 1985) 
and bovine species (Kanchev et al. 1988) in which a strong positive correlation was found 
between these two values for the length of the study. In cycling mare’s saliva P4 levels rose 
concurrently with serum P4 levels after ovulation, peaked by day 8 and subsequently declined 
after day 14. In pregnant mares the decline wasn’t significant; however at no point during the 
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entire study did salivary P4 values drop below 0.5 ng/ml after day 14. This level could be useful 
as a cutoff level to monitor the luteal phase or presence of an active corpus luteum in mares. 
Thus studies validating this cutoff value, with even greater number of mares in each group and a 
greater frequency of sampling need to be done.    
When percent Saliva: Serum ratio (Sa:Se ratio) was calculated, that percent salivary P4 
values were much higher during follicular phase, up to the day of ovulation. The values for 
cycling mares were 35% while those seen in the pregnant group of mares were around 25% of 
those seen in serum on day 1 post-ovulation. The percentages then dropped sharply by day 3 to 
less than half and then were maintained steadily between 8 to 11% till day 17 in cycling mares 
and throughout the study period (up to day 65) in pregnant mares. Similar findings have been 
noted by Kanchev et al. (1988) in their bovine salivary P4 study where they have seen values up 
to 15% in salivary levels of P4 during the follicular phase. These values are much higher than the 
values usually found in human saliva, where 2-10 % levels are considered as a thumb rule (Riad-
Fahmy et al. 1981). It may be possible to use this information for timing of ovulation studies in 
mares by monitoring the saliva: serum ratio. There however is a lot of debate as to why percent 
follicular levels are higher than luteal values during the estrous cycle. It may be possible that 
there may be a threshold level that needs to be maintained for salivary P4 and or that rapidly 
decreasing serum P4 levels during follicular phase somehow causes the dissociation of P4 from 
the carrier proteins it is bound to. Another explanation could be that the amount of P4 transferred 
across the salivary gland membrane is not determined only by the unbound concentration in 
plasma or serum. Similarly the ability of steroids to move across capillary membranes appears to 
depend on both the steroid and the organ containing the capillary bed (Verheugen et al. 1984). 
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Hence the study of passage of progesterone across salivary capillary beds may provide an idea as 
to why this phenomenon occurs.   
In humans, salivary P4 levels can be useful for the prediction of ovulation, demonstrating a 
correlation of 0.75 with serum P4 levels, and salivary estradiol and P4 levels can be used for the 
evaluation of ovarian function (Lu et al., 1997, 1999) or as a predictor of pre-term delivery 
(Darne et al., 1987). In mares the serum P4 levels usually decrease in the last 24-48 hours before 
parturition (Fowden et al. 2008). Thus assays studying the P4: Estradiol ratio might give valuable 
information regarding the impending parturition.  
The RIA set up for the present study showed a high specificity and a sensitivity of 16 pg. 
/tube. Volumes as less as 500 µL was sufficient to provide enough sample to run the assay. The 
saliva collection was done using disposable plastic pipettes instead of the conventional salivette 
system used commercially. This was done specifically to reduce any spurious increase in salivary 
P4 due to presence of cotton based absorptive material as demonstrated in previous studies 
(Shirtcliffe E.A. et al. 2001). The assay also demonstrated that salivary P4 could be assayed 
reliably without subjecting the sample to the lengthy extraction process. The present study has 
made an attempt to compare salivary and serum P4 in cycling and pregnant mares, because 
serum is usually used as a reference fluid for most assays.  However, it should be remembered 
that the P4 in both these different body fluids is in a free (saliva) and bound (serum) state. Our 
findings that saliva P4 levels do not reflect serum levels should not be interpreted as information 
of little use. Based on the results of the present study, more studies could in fact help establish 
the normal range of salivary P4 values for mares in different physiological stages of 
reproduction. The present study could be regarded as a pilot reference study, results of which 
could benefit similar studies in the future. 
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CHAPTER 6 
CONCLUSIONS 
 
The present study allowed us to conclude: 
• Salivary P4 can be reliably estimated in mare saliva during different stages of the estrous 
cycle and early gestation using a simple liquid phase RIA. 
• Saliva need not be subjected to lengthy solvent extraction for P4 estimation. Instead a 
neat sample can be assayed, thus reducing the time and labor. 
• Salivary P4 was not found to correlate statistically with serum P4 values. 
• Salivary P4 levels however do rise and fall in conjunction with serum levels during the 
estrous cycle in cycling mares and also during early gestation in pregnant mares. 
• Sa: Se ratio was seen to rise sharply during the follicular phase and drop post-ovulation. 
This ratio was found to be much higher in mares, when compared to similar data in 
humans and cattle. 
• Luteal phase saliva P4 levels were observed to be consistently above 0.5 ng/ml in both 
the both groups. 
• This preliminary data could be used for further studies in monitoring luteal function in 
mares. 
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CHAPTER 7 
TABLES AND FIGURES 
 
Table1. Time-points for saliva and serum sample collection in the Cycling Mare Group and their 
corresponding reproductive status. 
 
 
 
Day of the Sample Collection during 
the Estrous Cycle 
Reproductive Status 
1 Day of Ovulation 
3 CL still immature and forming 
5 Mature CL formed 
8 Peak P4 levels 
14 Maternal Recognition of Pregnancy 
17 Follicular phase  
20-22 Day of Ovulation 
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Table2. Time-points for saliva and serum sample collection in the Pregnant Mare Group and 
their corresponding reproductive status. 
 
  
 
Day of the Sample Collection during  
Estrous Cycle and Pregnancy 
Significance 
1 Day of Ovulation 
3 Immature CL 
5 Mature CL formed 
8 Peak P4 levels 
14 
Maternal Recognition of Pregnancy and 
Pregnancy Diagnosis 
17 Fixing of the Embryo  
25 Heart Beat Check 
35 Endometrial Cups Formed 
45 Assess Fetal Viability 
65 Fetal Sexing 
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Table3. RIA assay plot for setting up a Binding Efficiency Assay  
 
Tube No. ID 
STD or 
SAMPLE 
PBS-
Gel 
P4-Ab 3H-P4 
Charcoal 
Dextran 
1-2 BKGD 
 
400ul 
 
100ul 200ul 
3-4 Total 
 
600ul 
 
100ul 
 
5-6 Bound-Bo 
 
300ul 100ul 100ul 200ul 
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Table4. Preparation of Standards for the RIA 
 
Solution ID and Conc. 
(pg/100 µl) 
PBS Vol. (ml) Solution to Add (ml) 
Final Volume 
(ml) 
A  
(100,000) 
  0.5 
B (1000) 0.45 0.05 ml of A 0.5  
C (500) 7.125 0.375 ml of B 7.5 
D (50) 6.75 0.75 ml of C 7.5 
E (250) 2.5 2.5 ml of C 5 
F (125) 3.75 1.25 ml of C 5 
G (64) 4.37 0.63 ml of C 5 
H(32) 1.80 3.2 ml of D 5 
I (16) 3.40 1.6 ml of D 5 
J (8) 4.20 0.8 ml of D 5 
K (4) 4.60 0.4 ml of D 5 
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Table5. Assay Plot for Setting up a Standard Curve for the RIA 
 
Tube No. ID STD  PBS-Gel P4-Ab 3H-P4 
Charcoal 
Dextran 
1-2 BKGD 
 
400ul 
 
100ul 200ul 
3-4 Total 
 
600ul 
 
100ul 
 
5-6 Bound-Bo 
 
300ul 100ul 100ul 200ul 
7-8 Std 4 pg 100ul 200ul 100ul 100ul 200ul 
8-10 Std 8 pg 100ul 200ul 100ul 100ul 200ul 
11-12 Std 16 pg 100ul 200ul 100ul 100ul 200ul 
13-14 Std  32 pg 100ul 200ul 100ul 100ul 200ul 
15-16 Std 64 pg 100ul 200ul 100ul 100ul 200ul 
17-18 Std 125 pg 100ul 200ul 100ul 100ul 200ul 
19-20 Std 250 pg 100ul 200ul 100ul 100ul 200ul 
21-22 Std 500 pg 50ul 250ul 100ul 100ul 200ul 
23-24 Std. 1000 pg 100ul 200ul 100ul 100ul 200ul 
25-26 Bound-Bo  300ul 100ul 100ul 200ul 
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Table6. Assay Plot for Serum Sample Parallelism and Hot Recovery. Tube no. 21-30 represent 
the samples validated for parallelism. As the sample volume is increased, it is compensated by a 
decrease in the amount of PBS-Gel used. Tubes 36- 43 represent the samples used for validation 
of the unlabeled ligand (cold recovery). Here the sample volume is constant across the tubes. 
Tubes 50-55 represent the hot recovery vials containing 1/5th of the original mixture of sample 
and spike whereas tubes 56-57 are the spike controls.  
NAME DAY 1 DAY 2 DAY 3 
Tube No ID STD or SAMPLE PBS-Gel P4-Ab 3H-P4 
Charcoal 
Dextran 
1-2 BKGD 
 
400ul 
 
100ul 200ul 
3-4 Total 
 
600ul 
 
100ul 
 
5-6 Bound-Bo 
 
300ul 100ul 100ul 200ul 
7-8 Std 16pg 100ul 200ul 100ul 100ul 200ul 
9-10 Std 32pg 100ul 200ul 100ul 100ul 200ul 
11-12 Std 64pg 100ul 200ul 100ul 100ul 200ul 
13-14 Std 125pg 100ul 200ul 100ul 100ul 200ul 
15-16 Std 250pg 100ul 200ul 100ul 100ul 200ul 
17-18 Std 500pg 100ul 200ul 100ul 100ul 200ul 
19-20 Std 1000pg 100ul 200ul 100ul 100ul 200ul 
21-22 Serum  100ul 200ul 100ul 100ul 200ul 
23-24 Serum + 50 ul 150ul 150ul 100ul 100ul 200ul 
25-26 Serum + 100 ul 100ul 200ul 100ul 100ul 200ul 
27-28 Serum + 200 ul 200ul 100ul 100ul 100ul 200ul 
29-30 Serum + 300 ul 300ul - 100ul 100ul 200ul 
31-32 Internal Control 64pg 50ul 250ul 100ul 100ul 200ul 
33-34 Internal Control 125pg 100ul 200ul 100ul 100ul 200ul 
35-36 Bound-Bo  300ul 100ul 100ul 200ul 
36-37 Serum 100ul 200ul 100ul 100ul 200ul 
38-39 Serum + 50 pg 100ul 200ul 100ul 100ul 200ul 
40-41 Serum + 100 pg 100ul 200ul 100ul 100ul 200ul 
42-43 Serum + 200 pg 100ul 200ul 100ul 100ul 200ul 
44-45 Internal Control 64pg 50ul 250ul 100ul 100ul 200ul 
46-47 Internal Control 125pg 100ul 200ul 100ul 100ul 200ul 
48-49 Bound-Bo  300ul 100ul 100ul 200ul 
50-55 Hot Recovery Minivials 100 ul     
56-57 SPIKE Serum (minivial) 100 ul     
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Table7. Calculated means of standards as determined from the semi-log plot generated by 
assaying actual amounts of P4 
 
 
Standards Assayed (pg.) Amount Detected by the RIA (pg.) 
16  17.65 
32 29.04 
64 66.95 
125 124.19 
250 239.60 
500 558.52 
1000 937.55 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
Table8. Friedman’s Non-parametric One-way Analysis of Variance (ANOVA) for serum 
progesterone concentration’s in cycling mare group and Wilcoxon Signed Rank Test comparing 
each day to other days in the group. Statistical significance was set at p<0.05. 
i) Friedman’s Non-Parametric One-way ANOVA               
Test Statisticsa 
 
N 8 
Chi-Square 43.736 
df 6 
Asymp. Sig. .000 
a. Friedman’s Test 
 
ii) Wilcoxon Signed Rank Test for Day “1” with all other days’ 
 
 D3 - D1 D5 - D1 D8 - D1 D14 - D1 D17 - D1 D20 - D1 
Z -2.530b -2.546b -2.539b -2.271b -1.000c -.378c 
Asymp. Sig. (2-
tailed) .011 .011 .011 .023 .317 .705 
 
 
iii) Wilcoxon Signed Rank Test for group day “3” with other days’  
 
 D5 - D3 D8- D3 D14 - D3 D17 - D3 D20 - D3 
Z -2.546b -2.539b -.085c -2.527c -2.530c 
Asymp. Sig. (2-
tailed) .011 .011 .932 .012 .011 
 
iv) Wilcoxon Signed Rank Test for day “5” with other days  
 
 D8 - D5 D14 - D5 D17 - D5 D20 - D5 
Z -1.890b -2.375c -2.539c -2.565c 
Asymp. Sig. (2-
tailed) .059 .018 .011 .010 
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v) Wilcoxon Signed Rank Test for day “8” with other days 
 
 D14 - D8 D17 - D8 D20 - D8 
Z -2.524b -2.527b -2.536b 
Asymp. Sig. (2-
tailed) .012 .012 .011 
 
vi) Wilcoxon Signed Rank Test for day “14” with other days 
 
 D17- D14 D20 - D14 
Z -2.536b -2.379b 
Asymp. Sig. (2-tailed) .011 .017 
 
a. Wilcoxon Signed Rank Test 
b. Based on negative ranks. 
c. Based on positive ranks. 
D. Day  
Numbers highlighted in red are statistically significant (p<0.05). 
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Table9.  Mean progesterone concentrations in serum and saliva of cycling mares and pregnant 
mares and percent progesterone in saliva as compared to serum. 
i) Cycling Mares 
Day of Cycle Mean P4 in serum (ng/ml) ± S.E. 
Mean P4 in saliva 
(ng/ml) ± S.E. Saliva/Serum*100  
1 1.523 ± 0.378 0.533 ± 0.102 35.00% 
3 4.869 ± 0.841 0.622 ± 0.097 12.77% 
5 8.102 ± 0.744 0.731 ± 0.105 9.02% 
8 9.064 ± 0.675 0.762 ± 0.082 8.41% 
14 4.324 ± 0.566 0.539 ± 0.083 12.47% 
17 1.114 ± 0.190 0.334 ± 0.056 29.98% 
20 1.404 ± 0.177 0.507 ± 0.082 36.11% 
 
ii) Pregnant Mares 
Day of Cycle Mean P4 in serum (ng/ml) ± S.E. 
Mean P4 in saliva 
(ng/ml) ± S.E. Saliva/Serum*100 
1 1.322 ± 0.100 0.319 ± 0.025 24.13% 
3 3.755 ± 0.418 0.332 ± 0.037 8.84% 
5 5.928 ± 0.740 0.675 ± 0.106 11.39% 
8 7.858 ± 0.751 0.888 ± 0.129 11.30% 
14 5.658 ± 0.325 0.523 ± 0.040 9.24% 
17 5.041 ± 0.418 0.563 ± 0.049 11.17% 
25 4.769 ± 0.253 0.547 ± 0.059 11.47% 
35 5.877 ± 0.350 0.618 ± 0.043 10.52% 
45 7.304 ± 0.345 0.686 ± 0.060 9.39% 
65 7.066 ± 0.493 0.758 ± 0.140 10.73% 
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Table10. Friedman’s Non-parametric One-way Analysis of Variance (ANOVA) for saliva to 
serum  progesterone concentrations ratios in cycling mare group and Wilcoxon Signed Rank Test 
Statistical significance was set at p<0.05. 
i) Friedman’s Non-Parametric One-way ANOVA               
 
Test Statisticsa 
 
N 8 
Chi-Square 28.821 
df 6 
Asymp. Sig. .000 
a. Friedman Test 
 
ii) Wilcoxon Signed Rank Test for Saliva: Serum (Sa: Se) ratio of Day “1” and other day 
groups of cycling 
 
 D3 – D1 D5 – D1 D8 - D0 D14 – D1 D17- D1 D20 – D1 
Z -2.380b -2.521b -2.521b -2.240b -.840b -.420b 
Asymp. Sig. (2-tailed) .017 .012 .012 .025 .401 .674 
 
 
iii) Wilcoxon Signed Rank Test for Sa: Se ratio of Day “3” and other day groups of cycling 
 
 D5 - D3 D8 - D3 D141 - D31 D17 - D3 D20 - D3 
Z -1.540b -2.100b -.140b -1.820c -2.100c 
Asymp. Sig. (2-
tailed) .123 .036 .889 .069 .036 
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iv) Wilcoxon Signed Rank Test for Sa: Se ratio of Day “8,14,17 and 20” of  
cycling groups 
 
 D14 - D8 D17 - D8 D20- D8 D17 - D14 D20 - D14 D20 - D17 
Z -1.612b -2.521b -2.380b -2.521b -2.240b -.560b 
Asymp. Sig. (2-
tailed) .107 .012 .017 .012 .025 .575 
 
a. Wilcoxon Signed Rank Test 
b. Based on negative ranks. 
c. Based on positive ranks. 
D. Day 
Number’s highlighted in red are statistically significant (p<0.05) 
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Table11. Progesterone profiles in pregnant mare serum were statistically significant with a 
Friedman’s Chi-Square as well as a post-hoc comparison of each sampling period. The only day 
not contributing to significance levels was day 5. Statistical significance was set at p<0.05. 
i) Friedman’s Non-Parametric One-way ANOVA        
        
Test Statisticsa 
 
N 7 
Chi-Square 47.605 
df 9 
Asymp. Sig. .000 
 
 
ii) Wilcoxon Signed  Rank Test 
 
 D3 – D1 D5 – D1 D8 – D1 D14 – D1 D17 – D1 
Z -2.388b -2.384b -2.371b -2.388b -2.375b 
Asymp. Sig. (2-
tailed) .017 .017 .018 .017 .018 
 
 
iii) Wilcoxon Signed Rank Test for Day “3” and all other days                                 
 
 D5 - D3 D8 - D3 D14 - D3 D17 - D3 
Z -2.401b -2.207b -2.333b -2.041b 
Asymp. Sig. (2-
tailed) .016 .027 .020 .041 
 
iv) Wilcoxon Signed Rank Test for Day “3” and other days                                  
 
 D25 - D3 D35 - D3 D45 - D3 D65 - D3 
Z -2.271b -2.132b -2.410b -2.232b 
Asymp. Sig. (2-
tailed) .023 .033 .016 .026 
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v) Wilcoxon Signed Rank Test for Day “3” and other days                                                                            
 D14 - D80 D17 - D8 D25 - D8 D35 - D8 D45 - D8 D65 - D8 
Z -2.023b -2.214b -2.214b -2.414b -.862b -1.095b 
Asymp. Sig. (2-
tailed) .043 .027 .027 .016 .389 .273 
 
vi) Wilcoxon Signed Rank Test for Day “14” and other days                                                                             
 D17 - D14 D25 - D14 D35 - D14 D45 - D14 D65 - D14 
Z -1.633b -2.121b -.447c -2.232c -2.264c 
Asymp. Sig. (2-
tailed) .102 .034 .655 .026 .024 
 
vii) Wilcoxon Signed Rank Test for Day “17” and other days 
 D25 - D17 D35 - D17 D45 – D17 D65 - D17 
Z -.816b -1.289c -2.232c -2.226c 
Asymp. Sig. (2-
tailed) .414 .197 .026 .026 
 
viii) Wilcoxon Signed Rank Test for ay “25” and other days 
 D30 - D25 D45 - D25 D65 - D25 D45 - D35 D65 - D35 D65 - D45 
Z -1.823b -2.388b -2.214b -2.041b -2.060b -.816c 
Asymp. Sig. (2-
tailed) .068 .017 .027 .041 .039 .414 
 
a. Wilcoxon Signed Rank Test 
b. Based on negative ranks. 
c. Based on positive ranks. 
D. Day 
Number’s highlighted in red are statistically significant (p<0.05) 
48 
 
Table12. Progesterone profiles in pregnant mare saliva were statistically significant with a 
Friedman’s Chi-Square and a post-hoc comparison of each sampling period showed that values 
from Days 1 and 3 seemed to be contributing to that significance. Statistical significance was set 
at p<0.05. 
i)  Friedman’s Non-Parametric One Way ANOVA 
 
Test Statisticsa 
N 7 
Chi-Square 27.778 
df 9 
Asymp. Sig. .001 
a. Friedman Test 
ii) Wilcoxon Signed Rank Test for day “1” and other days 
 D3 – D1 D5 – D1 D8- D1 D14 – D1 D17 – D1 
Z .000b -2.000c -2.646c -2.000c -2.000c 
Asymp. Sig. (2-
tailed) 1.000 .046 .008 .046 .046 
 
 D25 – D1 D35 – D1 D45 – D1 D65 – D1 
Z -2.000b -2.449b -2.449b -2.236b 
Asymp. Sig. (2-
tailed) .046 .014 .014 .025 
 
iii) Wilcoxon Signed Rank Test for day “3” and other days 
 D5 - D3 D8 - D3 D14 - D3 D17 - D3 D25 - D3 
Z -2.000b -2.646b -2.000b -2.000b -2.000b 
Asymp. Sig. (2-
tailed) .046 .008 .046 .046 .046 
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 D35 - D3 D45 - D3 D65 - D3 
Z -2.449b -2.449b -2.236b 
Asymp. Sig. (2-
tailed) .014 .014 .025 
 
a. Wilcoxon Signed Rank Test 
b. Based on negative ranks. 
c. Based on positive ranks. 
D. Day 
Number’s highlighted in red are statistically significant (p<0.05) 
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Table13. Friedman’s Non-parametric One-way Analysis of Variance (ANOVA) for levels saliva 
to serum  progesterone ratio in pregnant group of mares and Wilcoxon Signed Rank Test. 
Statistical significance was set at p<0.05. 
i) Friedman’s Non-Parametric One Way ANOVA 
 
Test Statisticsa 
 
N 7 
Chi-Square 25.514 
df 9 
Asymp. Sig. .002 
 
ii) Wilcoxon Signed Rank Test for day “1” and other days 
 
 D3 – D1 D5 – D1 D8 – D1 D14 – D1 D17 – D1 
Z -2.371b -2.366b -2.366b -2.366b -2.366b 
Asymp. Sig. (2-
tailed) .018 .018 .018 .018 .018 
 
 D25 – D1 D35 – D1 D45 – D1 D65 – D1 
Z -2.366b -2.366b -2.366b -2.366b 
Asymp. Sig. (2-tailed) .018 .018 .018 .018 
 
a. Wilcoxon Signed Rank Test 
b. Based on negative ranks. 
c. Based on positive ranks. 
D. Day 
Number’s highlighted in red are statistically significant (p<0.05) 
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Table 14. Pearson’s Correlation Analysis to demonstrate overall correlation between salivary 
and serum progesterone concentrations in Cycling and Pregnant mares. 
i) Correlation between salivary P4 and serum P4 in cycling mares. 
Reproductive 
Status: 
Cycling 
Day 1 Day 3 Day5 Day 8 Day 14 Day17 Day20 
Correlation 
Coefficient 
0.698 -0.518 0.784 0.187 0.446 0.451 0.530 
p-value 0.054 0.189 0.021 0.165 0.268 0.262 0.175 
 
ii) Correlation between salivary and serum P4 in pregnant mares. 
Reproductive Status: 
Pregnant  
Day 1 Day 3 Day5 Day 8 Day 14 
Correlation 
Coefficient 
0.524 0.417 0.959 0.771 -0.020 
p-value 0.226 0.351 0.0006 0.042 0.965 
 
Reproductive Status: 
Pregnant  
Day 17 Day 25 Day 35 Day 45 Day 65 
Correlation 
Coefficient 
0.266 0.387 0.596 0.155 0.574 
p-value 0.563 0.391 0.157 0.739 0.177 
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Figure1. Standard curve generated shows a typical sigmoid shape with at least five standards 
fitting on the linear part of the curve, from 32pg. to 500 pg. Standards 4 and 8 pg. were below the 
sensitivity of the assay and were out of range. Hence these standards were not used. This 
standard curve gives a good quality of fit (R² = 0.999905) with an overall 42.64 % binding and 
low 1.86 % non-specific binding (NSB) as calculated by AssayZap. 
The X-axis represents the content of the standards (pg) whereas the Y-axis represents the percent 
bound in absence or presence of standards. With increasing amounts of unlabeled P4, lesser 
amount of 3H-P4 is bound to the P4 antibody. 
 
 
 
 
 
  
53 
 
Figure2. Graphical representation of progesterone profiles in serum and saliva of cycling mares 
(n =8). Friedman’s non-parametric one-way analysis of variance revealed significant differences 
in serum progesterone concentration by day of observation (Friedman’s Chi-Square=47.37 
p<0.0001). A Wilcoxon Signed Rank Test revealed significance between all days except day 17 
and 20. 
Friedman’s one way ANOVA showed no significant difference in salivary progesterone 
concentration by day of observation (Friedman’s Chi-Square = 8.46, p = 0.206). 
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Serum progesterone concentration comparison between time-points in cycling mares (p = 0.05) 
 
se3 se5 se8 se14 se17 se20 
se1 0.011 0.011 0.011 0.023 0.317 0.705 
se3 
 
0.011 0.011 0.932 0.012 0.011 
se5 
  
0.059 0.018 0.011 0.01 
se8 
   
0.012 0.012 0.011 
se14 
    
0.011 0.017 
se17 
     
0.083 
 
Saliva progesterone concentration comparison between time-points in cycling mares (p = 0.05) 
 
sa3 sa5 sa8 sa14 sa17 sa20 
sa1 1 0.083 0.317 0.317 0.157 1 
sa3 
 
0.083 0.317 0.564 0.414 1 
sa5 
  
0.564 0.157 0.025 0.18 
sa8 
   
0.564 0.102 0.317 
sa14 
    
0.083 0.655 
sa17 
     
0.317 
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Figure3. Graphical representation of progesterone profiles in serum and saliva of pregnant mares 
(n=7). There was a significant difference in the serum P4 concentration by day of observation in 
the pregnant mares (Friedman’s Chi-Square = 47.60, p<0.0001). Besides, the post-hoc pairwise 
comparison of each sampling period also showed significance for almost all sampling days. 
 Statistical significance in salivary P4 was seen after Friedman’s one way ANOVA, 
however only days 1 and 3 seemed to contribute to this significance. 
 
Pregnant Mare Data 
Mean ± SE for serum and saliva progesterone concentration for each time-point 
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Serum progesterone concentration comparison between time-points in pregnant mares (p = 0.05) 
 
se3 se5 se8 se14 se17 se25 se35 se45 se65 
se1 0.017 0.017 0.018 0.017 0.018 0.016 0.017 0.016 0.016 
se3 
 
0.016 0.027 0.02 0.041 0.023 0.033 0.016 0.026 
se5 
  
0.058 0.891 0.336 0.059 0.891 0.206 0.347 
se8 
   
0.043 0.027 0.027 0.016 0.389 0.273 
se14 
    
0.102 0.034 0.655 0.026 0.024 
se17 
     
0.414 0.197 0.026 0.026 
se25 
      
0.068 0.017 0.027 
se35 
       
0.041 0.039 
se45 
        
0.414 
 
Saliva progesterone concentration comparison between time-points in pregnant mares (p = 0.05) 
 
sa3 sa5 sa8 sa14 sa17 sa25 sa35 sa45 sa65 
sa1 1 0.046 0.008 0.046 0.046 0.046 0.014 0.014 0.025 
sa3 
 
0.046 0.008 0.046 0.046 0.046 0.014 0.014 0.025 
sa5 
  
0.083 1 1 1 0.317 0.317 0.317 
sa8 
   
0.083 0.083 0.083 0.317 0.317 0.157 
sa14 
    
1 1 0.317 0.317 0.564 
sa17 
     
1 0.317 0.157 0.317 
sa25 
      
0.157 0.317 0.564 
sa35 
       
1 0.564 
sa45 
        
0.564 
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Figure4. Graph showing the saliva to serum ratio (%) in cycling group mares. Days 1, 17 and 20 
of sample collection were seen to be statistically similar and differed from rest of the days. Days 
ranging from 3 to 14 were statistically similar to each other. Friedman’s one way ANOVA 
showed a Chi-square value of 28.82 p<0.0001.  
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Figure5. Graph showing the saliva to serum ratio (%) in pregnant group mares. Day 1differed 
statistically from rest of the sampling days. All other sampling days were statistically similar to 
each other. Friedman’s one way ANOVA showed a Chi-square value of 25.514 p<0.002. 
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